THE COMPANY AND ITS SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	1 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Net loss		$ (1,410,000)	$ (463,000)
Cash			137,000
Receive of Erc fund	$ 198,000
Consideration for the Asset Sale		3,000,000
Net cash (used in) / provided by operating activities		(768,000)	(673,000)
Net increase in / (decrease in) cash and cash equivalents		34,000	115,000
Working capital		(2,833,000)	(1,519,000)
Accumulated deficit		(25,223,000)	(23,813,000)
Allowance for doubtful accounts		2,000	3,000
Allowance for slow moving and obsolete inventory		$ 235,000	$ 278,000
Securities not included in diluted loss per share		1,736,000	1,937,000
Deferred compensation expenses		$ 10,000	$ 33,000
Stockholders' deficit		2,339,000	944,000	$ 1,256,000
Non Current laese asset		6,000
Current lease liability		4,000	35,000
Current lease asset		7,000
Non current laese asset		$ 6,000
Patent asset impairment		100,000
Loss on impairment		100,000
buildings [Member]
Useful life		30 years
Operating Activities [Member]
Net cash (used in) / provided by operating activities		$ 769,000	673,000
Minimum [Member]
Useful life		3 years
Maximum [Member]
Useful life		5 years
Security Agreement [Member]
Notes Payable		$ 1,000,000
Term 2020 [Member]
Notes Payable		240,000
Chief Executive Officer [Member]
Deferred compensation expenses		94,000	20,000
Payroll taxes		7,000
Total deferred		87,000
Ms Waterhouse [Member]
Amount owes		32,000
Senior Management [Member]
Amount owes		14,000
Payroll taxes due		1,000
Deferred compensation expenses		15,000
Healgen [Member]
Retention fund		300,000
Advance payment		715,000
Accounts Receivable | Customer One
Allowance for doubtful accounts		$ 2,000	$ 3,000
Concentration of credit risk		35.40%	64.50%
Accounts Receivable | Customer Two
Concentration of credit risk		17.24%	12.70%
Accounts Receivable | Customer Three
Concentration of credit risk		10.40%